Meta-analysis finds CRP has moderate accuracy for diagnosing diabetic foot osteomyelitis
This meta-analysis of 12 observational diagnostic studies (1828 total patients) with a retrospective cohort component (265 patients with diabetic foot, including 204 with osteomyelitis) assessed the diagnostic accuracy of C-reactive protein (CRP) for diabetic foot osteomyelitis (DFO). The comparator was the presence versus absence of DFO diagnosis.
In the retrospective cohort, CRP showed an area under the curve (AUC) of 0.63 (95% CI: 0.55, 0.71). The optimal cut-off value was 9.57 mg/l, yielding a sensitivity of 74% and specificity of 53%. The meta-analysis pooled results indicated a sensitivity of 74% (95% CI: 63-83%), specificity of 73% (95% CI: 65-79%), and an AUC of 0.79 (95% CI: 0.75, 0.82). A composite model using a 15.20 mg/l cut-off achieved 80% sensitivity but only 53% specificity.
Safety and tolerability data were not reported. Key limitations were not reported, but the evidence is based on observational diagnostic studies with a retrospective component. The practice relevance is restrained: CRP demonstrates moderate diagnostic utility for DFO and could function as a screening adjunct in clinical evaluation, but its standalone accuracy is insufficient for definitive diagnosis.